Phase 3 Clinical Trials With Primary Completion Dates in June 2023
This is a list of Phase 3 trials with primary completion dates in June 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ALVO | Alvotech | 2023-06-01 | Phase 3 | NCT05155293 | Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) |
| ANVS | Annovis Bio, Inc. | 2023-06-01 | Phase 3 | NCT05357989 | A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD |
| AXSM | Axsome Therapeutics, Inc. | 2023-06-01 | Phase 3 | NCT05059223 | A Study to Assess the Efficacy and Safety of AXS-12 (Reboxetine) in Patients With Narcolepsy |
| AXSM | Axsome Therapeutics, Inc. | 2023-06-01 | Phase 3 | NCT04947553 | Open-Label Safety Study of AXS-05 in Subjects With Alzheimer's Disease Agitation |
| CING | Cingulate Inc. | 2023-06-01 | Phase 3 | NCT05631626 | Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301. |
| CLVSQ | Clovis Oncology, Inc. | 2023-06-01 | Phase 3 | NCT04227522 | Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients |
| CORT | Corcept Therapeutics Incorporated | 2023-06-01 | Phase 3 | NCT04308590 | Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
| DBVT | DBV Technologies S.A. | 2023-06-01 | Phase 3 | NCT03859700 | Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children |
| EBS | Emergent BioSolutions Inc. | 2023-06-01 | Phase 3 | NCT05349617 | Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years |
| MMSI | Merit Medical Systems, Inc. | 2023-06-01 | Phase 3 | NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant |
| ORGO | Organogenesis Holdings Inc. | 2023-06-01 | Phase 3 | NCT04636229 | Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee |
| SAGE | Sage Therapeutics, Inc. | 2023-06-01 | Phase 3 | NCT03864614 | A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD) |
| SLNO | Soleno Therapeutics, Inc. | 2023-06-01 | Phase 3 | NCT03714373 | Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period |
| TNXP | Tonix Pharmaceuticals Holding Corp. | 2023-06-01 | Phase 3 | NCT05273749 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia |
| ZLDPF | Zealand Pharma A/S | 2023-06-01 | Phase 3 | NCT05378672 | A Research Study to Investigate the Safety and Effect of Dasiglucagon as a Hypoglycemia Rescue Therapy and How it Works in the Body of Children Under 6 Years of Age With Type 1 Diabetes |